Inhibitor Therapeutics, Inc. Cash Flow Statement
INTI|7 years of annual SEC 10-K data (FY2014-FY2021)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$220,433
FY2021
Free Cash Flow
N/A
FY2021
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2021
Inhibitor Therapeutics, Inc. used $220,433 in operating cash flow in FY2021.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -856.15 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Negative shareholders equity: Liabilities exceed assets
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|
| Net Income | -$298.6K | -$1.1M | -$4.6M | -$5.1M | -$7.0M | -$3.9M | -$4.0M |
| Operating Cash Flow | -$220.4K | -$825.4K | -$3.7M | -$2.9M | -$3.8M | -$2.3M | -$1.3M |
| Dividends Paid | - | $0 | - | - | - | - | - |